Transition Therapeutics, Inc. (NASDAQ: TTHI) 47.8% LOWER; Elan Corporation, plc (NYSE: ELN) and TTHI today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer's disease.
The AD201 study is evaluating three dose levels of ELND005 compared to placebo in 353 patients. The stock was also downgraded to Hold at Roth Capita.
STARLIMS Technologies Ltd. (Nasdaq: LIMS) 45.9% HIGHER; Abbott (NYSE:...
Post new comment